SCHEMBL2592830

SCHEMBL2592830

O=C(Cl)[C@H]1CCCN1Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.58
NPSR1 Q6W5P4 1/20 0.56
CCR4 P51679 1/20 0.51
SCN3A Q9NY46 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
CYP1A2 P05177 1/20 0.49
OPRL1 P41146 2/20 0.48
OPRM1 P35372 1/20 0.48
OPRK1 P41145 1/20 0.48
MCHR1 Q99705 1/20 0.48
CYP2C19 P33261 1/20 0.48
CNR2 P34972 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055319 1.00 SPHK1 (0.58) SPHK1NPSR1CCR4SCN3AALDH1A1
SCHEMBL3399606 1.00 SPHK1 (0.58) SPHK1NPSR1CCR4SCN3AALDH1A1
SCHEMBL408685 0.89 SPHK1 (0.71) SPHK1NPSR1CCR4SCN3AMAOA
SCHEMBL408684 0.89 SPHK1 (0.71) SPHK1NPSR1CCR4SCN3AMAOA
SCHEMBL5154674 0.89 SPHK1 (0.71) SPHK1NPSR1CCR4SCN3AMAOA
SCHEMBL2587055 0.89 CYP1A2 (0.60) SPHK1NPSR1CCR4CYP1A2OPRL1
SCHEMBL1972076 0.89 CYP1A2 (0.60) SPHK1NPSR1CCR4CYP1A2OPRL1
SCHEMBL27801286 0.89 NPSR1 (0.57) SPHK1NPSR1CCR4SCN3AALDH1A1
SCHEMBL1819248 0.89 CYP1A2 (0.60) SPHK1NPSR1CCR4CYP1A2OPRL1
Hydrochloric Acid SCHEMBL28533309 0.88 SPHK1 (0.70) SPHK1NPSR1CCR4SCN3AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011138795-A2 PROCESS FOR PREPARING (S)-10-ACETOXY-10,11-DIHYDRO-5H-DIBENZ[B,F] AZEPINE-5-CARBOXAMIDE MSN LABORATORIES LIMITED (IN) 2011-11-10 WO claimed
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-04-28 US disclosed
EP-3939954-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE Otsuka Pharmaceutical Co., Ltd. (JP) 2022-01-19 EP disclosed
CN-113518771-A Method for introducing deuterated lower alkyl into amine part of compound containing secondary amine 大塚制药株式会社 2021-10-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE MGMT, FANCD2, ADAR SPHK1 868/4885NPSR1 3935/4885CCR4 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.